Ketamine vs Antidepressants: What's Different (2026)

"Should I try ketamine instead of antidepressants?" is one of the most common questions in this field, and it contains a misunderstanding worth clearing up before any comparison: in European medicine, ketamine is not an alternative to antidepressants — it is an option that opens after antidepressants have been properly tried, and in its approved form it is taken together with one. This page puts the two side by side — mechanism, speed, durability, evidence, cost, access — so the conversation you have with your clinician starts from facts rather than headlines. If you are at the stage where antidepressants have already failed, the full map of options is in depression treatment isn't working.

TL;DR Conventional antidepressants (SSRIs, SNRIs and relatives) are the first-line depression medication everywhere in Europe: cheap, prescribable by any doctor, moderately effective on average, and slow — benefits build over two to six weeks. Ketamine works on a different brain system, can act within hours, and is the reason it exists in depression care at all — but the benefit of a single infusion usually fades within one to two weeks, and its use for depression is off-label. The approved relative, esketamine nasal spray (Spravato), is authorised only for defined situations — mainly depression that has failed two antidepressants — and only in combination with an SSRI or SNRI, taken under clinical supervision. Ketamine does not replace antidepressants; at best, it is added when they have not been enough.

Two different mechanisms, two different clocks

Antidepressants — SSRIs, SNRIs and their relatives — act on the brain's monoamine systems, chiefly serotonin and noradrenaline. Their clinical rhythm is familiar: a low starting dose, an effect that builds over two to six weeks, dose adjustments, and — when they work — continuation for months to prevent relapse (NICE NG222). Their average effect across trials is real and moderate, and it varies from person to person; a large share of people respond well to the first or second drug tried, which is exactly why the guidelines put them first.

Ketamine is a dissociative anaesthetic acting principally on the NMDA glutamate receptors — a different brain system from conventional antidepressants, which is why it can help people for whom standard drugs have not, and why it can act within days rather than weeks. Racemic ketamine, given as an intravenous infusion under monitoring, produces a rapid antidepressant effect that small controlled trials have shown consistently since 2006 (Zarate et al. 2006; Caddy et al. 2015, Cochrane). It has never been through regulatory approval as an antidepressant, so its use for depression is off-label: legal, but outside its licensed indication. Its close relative, esketamine nasal spray (Spravato), is an approved EU medicine for treatment-resistant depression — the two routes are compared in detail in Spravato vs ketamine infusions.

Fact box — ketamine vs antidepressants at a glance - Mechanism: antidepressants — serotonin/noradrenaline systems; ketamine — NMDA glutamate receptors. - Onset: antidepressants — two to six weeks; ketamine — hours to a day. - Durability: antidepressants — effect maintained by continued daily treatment; ketamine — benefit of a single infusion usually fades within one to two weeks, repeat dosing needed. - Regulatory status: antidepressants — approved first-line medicines; IV ketamine — off-label for depression everywhere in Europe; esketamine (Spravato) — EU-approved for treatment-resistant depression, in combination with an SSRI or SNRI. - Who prescribes: antidepressants — any doctor, usually a GP; ketamine/esketamine — specialist settings, esketamine started by a psychiatrist and taken under direct supervision in a clinic. - Cost to you: antidepressants — cents per day, reimbursed everywhere; IV ketamine — mostly private, roughly €200-300 per session in continental Europe, £265-595 in the UK; esketamine — publicly reimbursed in much of continental Europe within the label. - Main risks: antidepressants — side effects vary by class (sexual dysfunction, weight, sleep, discontinuation symptoms); ketamine — dissociation and blood-pressure rise during sessions; with repeated use, bladder damage and dependence risks.

Speed: the real difference, and its limits

The single fact that made ketamine famous in psychiatry is genuine: relief can arrive within hours to a day of an infusion, which is unlike anything else in depression care — the foundational trial recorded response rates around 70% at 24 hours, in just 17 patients (Zarate et al. 2006). Conventional antidepressants cannot do this; their two-to-six-week onset is one of the hardest parts of depression treatment, because it asks the most patience of people who have the least to spare.

But speed is only half the clock. The benefit of a single ketamine infusion usually fades within one to two weeks, repeated infusions are needed to maintain it, and relapse after stopping is common (Marcantoni et al. 2020). A conventional antidepressant that works has the opposite profile: slow to start, but designed to hold — guidelines recommend continuing for at least six months after recovery precisely because the maintained effect is the point (NICE NG222). Fast-but-fading versus slow-but-holding is the one-line summary of this comparison, and it is why the two are increasingly discussed as complements rather than rivals.

Where each belongs in European treatment

Here the guidelines are unambiguous. Antidepressants — alongside psychological therapy — are the first-line medication for moderate to severe depression in every European guideline, and nothing about ketamine changes that. Ketamine and esketamine enter the picture at a defined later point: the treatment-resistant stage, conventionally meaning at least two adequate antidepressant courses that have not helped in the current episode. That is not bureaucratic gatekeeping; it reflects the evidence. Most people with depression never need anything beyond the standard options, the standard options are vastly better studied, and the rapid-acting routes carry their own burdens — supervised clinic sessions, monitoring, off-label status or strict reimbursement criteria.

Esketamine's EU label encodes this position precisely: it is authorised "in combination with an SSRI or SNRI, indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode" (EMA EPAR). Note both halves: after two failed antidepressants, and in combination with one — the approved rapid-acting medicine is an addition to antidepressant treatment, not a successor to it. The full trial record, including its mixed results and the suicidality question, is in our esketamine evidence review.

"Can ketamine replace my antidepressant?"

No — and it is worth being blunt, because clinic marketing sometimes implies otherwise. Three separate reasons stack up. First, the approved form is explicitly a combination treatment: esketamine's label requires an ongoing SSRI or SNRI alongside it. Second, ketamine's effect profile cannot do an antidepressant's job: a medicine whose single-dose benefit fades within one to two weeks is not a maintenance treatment unless dosing is repeated indefinitely — and long-term repeated ketamine carries documented risks of bladder and urinary-tract damage, dependence and, less commonly, liver injury (ketamine evidence review). Third, nobody has shown it can: there are no trials establishing ketamine monotherapy as a long-term replacement for antidepressant treatment. What the evidence supports is narrower and still valuable: rapid, supervised help at the treatment-resistant stage, layered onto ongoing care. If you want to stop an antidepressant — because of side effects, or because it is not working — that is a legitimate conversation to have with your prescriber about switching, tapering or augmenting (the options ladder), not a decision ketamine makes for you.

Cost and access: the stark asymmetry

Antidepressants are among the cheapest medicines in existence — generic SSRIs cost cents per day and are reimbursed by every European health system, prescribed in any GP surgery. The rapid-acting routes run on entirely different economics. IV ketamine for depression is a largely private market: in our verified listings, private per-infusion fees run roughly £265-595 in the UK and around €200-300 per session in much of continental Europe, with an induction series multiplying that by six or more (cost guide); public funding is uncommon — Norway is the notable exception, funding IV ketamine publicly since August 2025. Esketamine rides the approved medicine's rails instead: publicly reimbursed in much of continental Europe for exactly the two-failed-antidepressants situation — Germany, Spain, Poland and Scotland among the systems with working routes — which makes it, where you qualify, an ordinary insurance-funded next step rather than a purchase (where in Europe). Whether you qualify is checkable: our eligibility check walks the criteria country by country.

Frequently asked questions

Is ketamine better than antidepressants?

Wrong axis. Ketamine is faster; antidepressants are better studied, cheaper, easier to access and built for maintenance. For most people with depression, antidepressants (with therapy) are the evidence-based starting point and work well enough that ketamine never comes up. Ketamine's place is at the treatment-resistant stage — rapid help when standard drugs have failed, added to ongoing care, not instead of it.

Can I take ketamine while on an SSRI?

In the approved pathway you must: esketamine is authorised only in combination with an SSRI or SNRI, and trial protocols for IV ketamine typically continue existing antidepressants too. Unlike the classic psychedelics, ketamine's antidepressant effect does not require stopping serotonergic medication. Specific combinations and interactions are for your prescriber to assess — bring your full medication list.

How quickly does each one work?

Antidepressants: benefits build over two to six weeks, with dose adjustments often needed. Ketamine: within hours to a day of an infusion — and the benefit of a single infusion usually fades within one to two weeks, which is why clinics treat in series and why the speed advantage does not settle the comparison on its own.

Why would anyone choose the slow option?

Because slow-but-holding beats fast-but-fading for long-term illness, and because the slow option is approved, reimbursed, prescribable by your GP and backed by decades of evidence. The realistic question is rarely either/or: it is whether, after antidepressants have genuinely been tried, adding a rapid-acting option is worth its costs and burdens — a specialist conversation, mapped in our options guide.

Where do I start if antidepressants haven't worked?

With the record, then the country. Write down every antidepressant you have tried — name, highest dose, duration, result; two adequate failed courses in the current episode is the key that opens the treatment-resistant doors, including reimbursed esketamine in much of Europe. Then check your country's actual routes: our eligibility check and country guides map them, and the directory lists verified providers.

Sources

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Never stop or change an antidepressant without medical supervision — discontinuation needs planning with your prescriber. Discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number (112 in the EU) or a crisis line immediately.

Ketamine vs Antidepressants: What's Actually Different (2026)

On this page